Compare · DXCM vs OFIX
DXCM vs OFIX
Side-by-side comparison of DexCom Inc. (DXCM) and Orthofix Medical Inc. (OFIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and OFIX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 85.7x OFIX ($392.7M).
- Over the past year, DXCM is up 17.1% and OFIX is down 33.7% - DXCM leads by 50.8 points.
- DXCM has been more active in the news (9 items in the past 4 weeks vs 6 for OFIX).
- DXCM has more recent analyst coverage (25 ratings vs 10 for OFIX).
- Company
- DexCom Inc.
- Orthofix Medical Inc.
- Price
- $89.16-2.09%
- $9.63-1.68%
- Market cap
- $33.65B
- $392.7M
- 1M return
- +21.53%
- -18.90%
- 1Y return
- +17.08%
- -33.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1992
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 10
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest OFIX
- President, Global Limb Recon Fisher Patrick sold $13,067 worth of shares (1,295 units at $10.09), decreasing direct ownership by 2% to 51,219 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by Large owner Juniper Investment Company, Llc
- SEC Form S-8 filed by Orthofix Medical Inc.
- SEC Form 10-Q filed by Orthofix Medical Inc.
- Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
- MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
- Orthofix to Participate in Upcoming Investor Conferences
- Orthofix to Report Second Quarter 2026 Financial Results
- Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure